.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD13_RabeprazoleAmoxicillinAn.RabeprazoleAmoxicillinAn .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD13_RabeprazoleAmoxicillinAn.RabeprazoleAmoxicillinAn| name: | RabeprazoleAmoxicillinAndMetronidazole | |
| ATC code: | A02BD13 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 29 | L |
| clearance: | 12 | L/h |
| other parameters in model implementation | ||
This combination drug is a triple therapy regimen used for the eradication of Helicobacter pylori infection, most commonly in the treatment of peptic ulcers and gastritis associated with H. pylori. Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, while amoxicillin and metronidazole are antibiotics. This regimen is commonly approved and in use today for H. pylori eradication.
No published population pharmacokinetic models exist for the fixed combination; parameters estimated using average values of individual drugs in healthy adults after oral administration.